Biotimize
We are pleased to announce that the development of our CDMO's conceptual, basic and executive projects has begun!
Last month we closed a partnership with PQE Group to develop the Conceptual, Basic and Executive projects of our CDMO.
PQE Group is an ISO 9001 certified technology solutions and compliance consulting services company with global capabilities deliverable throughout the entire product quality life cycle. With offices located worldwide and a full-ranged broad service portfolio, extensive experience, effective project management, PQE’s solutions are the winning combination for global corporations, as well as small and medium sized companies.
With a total available area of more than 5,000 m2, Biotimize will build its new R&D Center (GLP) and CDMO (GMP) in a space of approximately 3,000 m2, in Piracicaba/SP. The objective of the CDMO (GMP) is to generate cell banks (WCB and MCB), produce clinical materials (phase I-III) and commercial batches focused on the mammalian cell expression platform. Furthermore, the R&D Center will be used for cell line development, process development, formulation development, development of analytical methods and production of pre-clinical materials from different expression platforms.
In the outlined roadmap, the executive project will be completed in June 2024, and as a result, the construction of the R&D Center and CDMO will begin. The expectation is that the new R&D Center will be inaugurating in the first quarter of 2025, and the CDMO, in the first quarter of 2026.
Want to know more about our expansion project? Access our website!
During the past decade, a significant shift has been seen in the nature of the products manufactured and sold by the innovative biopharmaceutical industry. The global biopharmaceutical portfolio of today contains a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise in treatments for many orphan… Continue reading Why do we need a CDMO?
In our last post, we talked about the CDMO importance (Why do we need a CDMO?). Now that it is clear, we need to understand what the key considerations are to choose the right CDMO for your process. Choosing a CDMO is something highly strategic and delicate, since the wrong choice can negatively impact the… Continue reading How to select the best CDMO for your needs?
Biotimize - Biotechnology as a Service is committed to complying with the laws that protect the privacy of the data of its employees, partners and the general public.
See how we deal with the information collected:
What are the data types?
Personal data:
”Information related to the identified or viral person”, for example: first name, last name, date of birth, personal documents, home or business address, telephone, email and IP address.
Sensitive Personal data:
These are the data that refer to racial or ethnic origin, religious conviction, political opinion, union affiliation or organization of a religious, philosophical or political nature. Sensitive personal data as well are those related to health or sex life, genetic or biometric data.
What data does our Company collect?
Our company handles data from employees, partners and service providers, being duly compliant with the LGPD.
On the website, the company collects data through the voluntary and consensual completion of forms, e-books and contact to receive the newsletter.
Is there automatic data collection? Biotimize - Biotechnology as a Service does not automatically collect data in each access to the website.
How do they use my data?
The personal data provided by users who fill in the forms are used solely to provide feedback at the user's request (individual or legal entity interested in our company's products and services).
Once the service is completed, such data is deleted.
Have you got any questions?
Talk to the Data Protection Manager (DPO) by email: dpo@biotimize.com.br
You will be able to clarify doubts related to the processing of personal data.
